NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis $62.39 -5.09 (-7.54%) As of 12:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About BioMarin Pharmaceutical Stock (NASDAQ:BMRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BMRN alerts:Sign Up Key Stats Today's Range$62.44▼$66.4950-Day Range$61.73▼$72.8352-Week Range$60.63▼$94.85Volume1.27 million shsAverage Volume1.85 million shsMarket Capitalization$11.90 billionP/E Ratio28.36Dividend YieldN/APrice Target$94.00Consensus RatingModerate Buy Company OverviewBioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Read More… Remove Ads BioMarin Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreBMRN MarketRank™: BioMarin Pharmaceutical scored higher than 98% of companies evaluated by MarketBeat, and ranked 13th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 17 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioMarin Pharmaceutical's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth38.41% Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 38.41% in the coming year, from $3.15 to $4.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 30.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.77.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 30.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.12.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 0.61. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioMarin Pharmaceutical's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.55% of the float of BioMarin Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 12.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Sustainability and ESG3.3 / 5Environmental Score-2.93 Percentage of Shares Shorted2.55% of the float of BioMarin Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 12.50%, indicating that investor sentiment is decreasing significantly. News and Social Media3.5 / 5News Sentiment1.21 News SentimentBioMarin Pharmaceutical has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 31 news articles for BioMarin Pharmaceutical this week, compared to 11 articles on an average week.Search InterestOnly 10 people have searched for BMRN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows16 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $184,521.00 in company stock.Percentage Held by InsidersOnly 1.85% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioMarin Pharmaceutical's insider trading history. Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRN Stock News HeadlinesTruist Financial Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)April 3 at 7:50 PM | markets.businessinsider.comBioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label ExpansionApril 3 at 3:38 PM | seekingalpha.comFBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” by several years…April 4, 2025 | Colonial Metals (Ad)BioMarin: Phase 3 PEGASUS trial of Palynziq met primary endpointApril 3 at 4:41 AM | markets.businessinsider.comBioMarin Pharmaceutical (NASDAQ:BMRN) Rating Lowered to Buy at StockNews.comApril 3 at 1:27 AM | americanbankingnews.comBioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent PatientsApril 2 at 3:33 PM | finance.yahoo.comBioMarin Pharmaceutical: Promising Growth Driven by Palynziq Success and Pipeline OpportunitiesApril 2 at 2:29 PM | tipranks.comIs BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now?April 2 at 10:30 AM | insidermonkey.comSee More Headlines BMRN Stock Analysis - Frequently Asked Questions How have BMRN shares performed this year? BioMarin Pharmaceutical's stock was trading at $65.73 on January 1st, 2025. Since then, BMRN stock has increased by 2.7% and is now trading at $67.48. View the best growth stocks for 2025 here. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its quarterly earnings data on Wednesday, February, 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.18. The biotechnology company had revenue of $747.31 million for the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a trailing twelve-month return on equity of 9.91%. Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's top institutional investors include Central Pacific Bank Trust Division and MassMutual Private Wealth & Trust FSB. Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Richard A Meier, Jeffrey Robert Ajer, Brian Mueller, Charles Greg Guyer, George Eric Davis, V Bryan Lawlis, Erin Burkhart and Mark J Alles. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Incyte (INCY), NVIDIA (NVDA), Meta Platforms (META), First Solar (FSLR), (MDVN) (MDVN) and Broadcom (AVGO). Company Calendar Last Earnings2/19/2025Today4/04/2025Next Earnings (Estimated)4/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,401Year Founded1997Price Target and Rating Average Stock Price Target$94.00 High Stock Price Target$126.00 Low Stock Price Target$65.00 Potential Upside/Downside+39.3%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)$2.20 Trailing P/E Ratio30.67 Forward P/E Ratio21.42 P/E Growth0.61Net Income$167.65 million Net Margins14.96% Pretax Margin18.98% Return on Equity9.91% Return on Assets7.65% Debt Debt-to-Equity Ratio0.11 Current Ratio5.33 Quick Ratio2.62 Sales & Book Value Annual Sales$2.85 billion Price / Sales4.51 Cash Flow$3.19 per share Price / Cash Flow21.17 Book Value$29.69 per share Price / Book2.27Miscellaneous Outstanding Shares190,777,000Free Float187,057,000Market Cap$12.87 billion OptionableOptionable Beta0.30 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:BMRN) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredThe bigger story behind the recent market pullbackNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.